Venous thromboembolism in hematopoietic stem cell transplant recipients

S. Chaturvedi, A. Neff, A. Nagler, U. Savani, M. Mohty, B. N. Savani

Research output: Contribution to journalReview articlepeer-review

Abstract

Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.

Original languageEnglish (US)
Pages (from-to)473-478
Number of pages6
JournalBone marrow transplantation
Volume51
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Venous thromboembolism in hematopoietic stem cell transplant recipients'. Together they form a unique fingerprint.

Cite this